AT501088A2 - Stabile therapeutische proteine - Google Patents

Stabile therapeutische proteine Download PDF

Info

Publication number: AT501088A2
Authority: AT; Austria
Prior art keywords: therapeutic proteins; fibrinogen; enzymes; enzyme; thrombin
Prior art date: 2002-12-18

Application number

AT0189002A

Other languages

German (de)

English (en)

Original Assignee

Bio Prod & Bio Eng Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-18

Filing date

2002-12-18

Publication date

2006-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32512947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT501088(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-18 Application filed by Bio Prod & Bio Eng Ag filed Critical Bio Prod & Bio Eng Ag

2002-12-18 Priority to AT0189002A priority Critical patent/AT501088A2/de

2003-12-18 Priority to ES03781990.1T priority patent/ES2476815T3/es

2003-12-18 Priority to EP10014814A priority patent/EP2292255A3/fr

2003-12-18 Priority to PCT/AT2003/000374 priority patent/WO2004054607A2/fr

2003-12-18 Priority to EP03781990.1A priority patent/EP1572229B1/fr

2003-12-18 Priority to AU2003289742A priority patent/AU2003289742A1/en

2003-12-18 Priority to DK03781990.1T priority patent/DK1572229T3/da

2005-06-17 Priority to US11/155,416 priority patent/US7795399B2/en

2006-06-15 Publication of AT501088A2 publication Critical patent/AT501088A2/de

2010-09-10 Priority to US12/879,821 priority patent/US20110009324A1/en

Links

102000004169 proteins and genes Human genes 0.000 title claims description 75
108090000623 proteins and genes Proteins 0.000 title claims description 75
230000001225 therapeutic effect Effects 0.000 title claims description 60
102000004190 Enzymes Human genes 0.000 claims description 64
108090000790 Enzymes Proteins 0.000 claims description 64
229940088598 enzyme Drugs 0.000 claims description 62
108010049003 Fibrinogen Proteins 0.000 claims description 54
102000008946 Fibrinogen Human genes 0.000 claims description 54
108090000190 Thrombin Proteins 0.000 claims description 54
229940012952 fibrinogen Drugs 0.000 claims description 53
229960004072 thrombin Drugs 0.000 claims description 53
230000000694 effects Effects 0.000 claims description 45
108010054218 Factor VIII Proteins 0.000 claims description 28
102000001690 Factor VIII Human genes 0.000 claims description 28
108091005804 Peptidases Proteins 0.000 claims description 28
229960000301 factor viii Drugs 0.000 claims description 28
239000004365 Protease Substances 0.000 claims description 26
238000000034 method Methods 0.000 claims description 26
239000000758 substrate Substances 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 21
238000003860 storage Methods 0.000 claims description 20
102000035195 Peptidases Human genes 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 19
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
238000000746 purification Methods 0.000 claims description 16
108010062466 Enzyme Precursors Proteins 0.000 claims description 15
102000010911 Enzyme Precursors Human genes 0.000 claims description 15
239000003112 inhibitor Substances 0.000 claims description 14
241000700605 Viruses Species 0.000 claims description 13
230000002255 enzymatic effect Effects 0.000 claims description 11
239000002532 enzyme inhibitor Substances 0.000 claims description 10
239000000126 substance Substances 0.000 claims description 10
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 9
238000011534 incubation Methods 0.000 claims description 9
230000008569 process Effects 0.000 claims description 9
230000009471 action Effects 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
230000002779 inactivation Effects 0.000 claims description 8
239000000543 intermediate Substances 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
239000007858 starting material Substances 0.000 claims description 7
230000004913 activation Effects 0.000 claims description 6
239000004019 antithrombin Substances 0.000 claims description 6
230000003196 chaotropic effect Effects 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
238000001728 nano-filtration Methods 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 6
239000007795 chemical reaction product Substances 0.000 claims description 5
239000003593 chromogenic compound Substances 0.000 claims description 5
238000009472 formulation Methods 0.000 claims description 5
150000002500 ions Chemical class 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
239000003153 chemical reaction reagent Substances 0.000 claims description 4
230000007774 longterm Effects 0.000 claims description 4
239000000178 monomer Substances 0.000 claims description 4
239000011148 porous material Substances 0.000 claims description 4
239000002028 Biomass Substances 0.000 claims description 3
230000000735 allogeneic effect Effects 0.000 claims description 3
230000009918 complex formation Effects 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
238000001514 detection method Methods 0.000 claims description 3
238000002523 gelfiltration Methods 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
238000012369 In process control Methods 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
239000002131 composite material Substances 0.000 claims description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
239000007850 fluorescent dye Substances 0.000 claims description 2
238000004128 high performance liquid chromatography Methods 0.000 claims description 2
230000001900 immune effect Effects 0.000 claims description 2
230000001771 impaired effect Effects 0.000 claims description 2
238000010965 in-process control Methods 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
238000004949 mass spectrometry Methods 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
239000006225 natural substrate Substances 0.000 claims description 2
239000007800 oxidant agent Substances 0.000 claims description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
230000002797 proteolythic effect Effects 0.000 claims description 2
230000003253 viricidal effect Effects 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
239000012084 conversion product Substances 0.000 claims 1
239000013583 drug formulation Substances 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 57
239000000243 solution Substances 0.000 description 32
JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 20
101800000974 Fibrinopeptide A Proteins 0.000 description 20
102400000525 Fibrinopeptide A Human genes 0.000 description 20
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
239000006228 supernatant Substances 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
229940006607 hirudin Drugs 0.000 description 13
108010073385 Fibrin Proteins 0.000 description 9
102000009123 Fibrin Human genes 0.000 description 9
239000004471 Glycine Substances 0.000 description 9
229950003499 fibrin Drugs 0.000 description 9
239000000523 sample Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
238000002835 absorbance Methods 0.000 description 7
230000007017 scission Effects 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 6
239000000440 bentonite Substances 0.000 description 6
229910000278 bentonite Inorganic materials 0.000 description 6
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 6
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
238000011026 diafiltration Methods 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
108010073651 fibrinmonomer Proteins 0.000 description 5
239000013049 sediment Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
108010094028 Prothrombin Proteins 0.000 description 4
108010039286 S 2238 Proteins 0.000 description 4
229940122388 Thrombin inhibitor Drugs 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000007979 citrate buffer Substances 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000003868 thrombin inhibitor Substances 0.000 description 4
108010054265 Factor VIIa Proteins 0.000 description 3
108010007267 Hirudins Proteins 0.000 description 3
102000007625 Hirudins Human genes 0.000 description 3
102100027378 Prothrombin Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 3
108010000499 Thromboplastin Proteins 0.000 description 3
102000002262 Thromboplastin Human genes 0.000 description 3
229940000635 beta-alanine Drugs 0.000 description 3
108090001015 cancer procoagulant Proteins 0.000 description 3
230000008859 change Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000010257 thawing Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
108010071289 Factor XIII Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
FIBJDTSHOUXTKV-BRHMIFOHSA-N lepirudin Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O FIBJDTSHOUXTKV-BRHMIFOHSA-N 0.000 description 2
230000037361 pathway Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000001226 reprecipitation Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000008016 vaporization Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
102100029117 Coagulation factor X Human genes 0.000 description 1
101710197191 Coagulation factor XIII A chain Proteins 0.000 description 1
102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
101800003778 Fibrinopeptide B Proteins 0.000 description 1
102400001063 Fibrinopeptide B Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
229940105756 coagulation factor x Drugs 0.000 description 1
229940105784 coagulation factor xiii Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
229940012414 factor viia Drugs 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
238000012432 intermediate storage Methods 0.000 description 1
108010002230 lepirudin Proteins 0.000 description 1
229960004408 lepirudin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000005259 measurement Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
229940030915 refludan Drugs 0.000 description 1
230000010076 replication Effects 0.000 description 1
239000012465 retentate Substances 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
239000012905 visible particle Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT0189002A 2002-12-18 2002-12-18 Stabile therapeutische proteine AT501088A2 (de)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
AT0189002A AT501088A2 (de)	2002-12-18	2002-12-18	Stabile therapeutische proteine
ES03781990.1T ES2476815T3 (es)	2002-12-18	2003-12-18	Fibrin�geno terapéutico estable
EP10014814A EP2292255A3 (fr)	2002-12-18	2003-12-18	Proteines thérapeutiques stables
PCT/AT2003/000374 WO2004054607A2 (fr)	2002-12-18	2003-12-18	Proteines therapeutiques stables
EP03781990.1A EP1572229B1 (fr)	2002-12-18	2003-12-18	Fibrinogen therapeutique stable
AU2003289742A AU2003289742A1 (en)	2002-12-18	2003-12-18	Stable therapeutic proteins
DK03781990.1T DK1572229T3 (da)	2002-12-18	2003-12-18	Stabilt terapeutisk fibrinogen
US11/155,416 US7795399B2 (en)	2002-12-18	2005-06-17	Stable therapeutic proteins
US12/879,821 US20110009324A1 (en)	2002-12-18	2010-09-10	Stable Therapeutic Proteins

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AT0189002A AT501088A2 (de)	2002-12-18	2002-12-18	Stabile therapeutische proteine

Publications (1)

Publication Number	Publication Date
AT501088A2 true AT501088A2 (de)	2006-06-15

Family

ID=32512947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT0189002A AT501088A2 (de)	2002-12-18	2002-12-18	Stabile therapeutische proteine

Country Status (7)

Country	Link
US (2)	US7795399B2 (fr)
EP (2)	EP1572229B1 (fr)
AT (1)	AT501088A2 (fr)
AU (1)	AU2003289742A1 (fr)
DK (1)	DK1572229T3 (fr)
ES (1)	ES2476815T3 (fr)
WO (1)	WO2004054607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT407484B (de) *	1997-11-12	2001-03-26	Bio Prod & Bio Eng Ag	Arzneimittel zur förderung der wundheilung
EP1458408B1 (fr)	2001-12-21	2009-04-15	Novo Nordisk Health Care AG	Composition liquide de polypeptides de facteur vii
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
CN1671410B (zh)	2002-06-21	2010-05-12	诺和诺德医疗保健公司	因子ⅶ多肽的稳定化固体组合物
AT501088A2 (de) *	2002-12-18	2006-06-15	Bio Prod & Bio Eng Ag	Stabile therapeutische proteine
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
RU2364609C2 (ru)	2003-05-23	2009-08-20	Ново Нордиск Хелт Кэр Аг	Стабилизация белка в растворе
EP1641487B1 (fr)	2003-06-25	2012-02-29	Novo Nordisk Health Care AG	Composition liquide de polypeptides du facteur vii
WO2005002615A1 (fr) *	2003-07-01	2005-01-13	Novo Nordisk Health Care Ag	Preparations pharmaceutiques aqueuses liquides de polypeptides facteur vii
JP5653572B2 (ja)	2003-08-14	2015-01-14	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh)	2003-12-19	2012-03-21	诺和诺德医疗保健公司	因子vii多肽的稳定化固体组合物
TWI270375B (en) *	2004-06-29	2007-01-11	Cheng-Yao Su	A method for preserving platelets outside a living body
US7659052B2 (en) *	2004-06-29	2010-02-09	Cheng Yao Su	Medium comprising cryoprecipitate and method for preserving platelets, red blood cells and other cells without a nucleus
FR2887883B1 (fr)	2005-06-29	2007-08-31	Lab Francais Du Fractionnement	Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1935429A1 (fr)	2006-12-22	2008-06-25	CSL Behring GmbH	Utilisation thérapeutique synergique de concentrés de complexe prothrombinique avec des concentrés de FVIII
EP2293776B8 (fr)	2008-06-23	2016-05-11	Bio-Products & Bio-Engineering Aktiengesellschaft	Fibrinogen étant fontionellement intact, stable au stockage et inactivé de virus
EP2305289A1 (fr) *	2009-09-16	2011-04-06	Bio-Products & Bio-Engineering Aktiengesellschaft	Produits médicinaux pour le traitement de troubles de la coagulation sanguine
RU2603103C2 (ru)	2010-09-20	2016-11-20	Октафарма Аг	Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт
RU2462255C1 (ru) *	2011-06-23	2012-09-27	Общество с ограниченной ответственностью Научно-производственное объединение "ЛИОМАТРИКС"	Органоспецифический регенерант gi
MX351340B (es)	2012-03-13	2017-10-11	Octapharma Ag	Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este.
TWI731108B (zh) *	2016-06-24	2021-06-21	徐家祥	具有止血功能的醫藥組合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT359646B (de) *	1979-04-19	1980-11-25	Immuno Ag	Verfahren zur herstellung von nebenwirkungs- freien plasmafraktionen
DE2916711A1 (de) *	1979-04-25	1980-11-06	Behringwerke Ag	Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4440679A (en) *	1980-03-05	1984-04-03	Cutter Laboratories, Inc.	Pasteurized therapeutically active protein compositions
US4348384A (en) *	1980-10-17	1982-09-07	Dainippon Pharmaceutical Co., Ltd.	Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5614500A (en) *	1983-03-04	1997-03-25	The Scripps Research Institute	Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US5149787A (en)	1984-05-22	1992-09-22	The Blood Center Research Foundation	Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4710381A (en)	1984-05-22	1987-12-01	The Blood Center Of Southeastern Wisconsin	Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
AT391808B (de) *	1986-11-03	1990-12-10	Immuno Ag	Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
GB8628108D0 (en) *	1986-11-25	1986-12-31	London Biotechnology Ltd	Riboflavin-linked assay
DE3640513A1 (de) *	1986-11-27	1988-06-09	Biotest Pharma Gmbh	Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
US5175087A (en) *	1987-07-06	1992-12-29	Biopool International, Inc.	Method of performing tissue plasminogen activator assay
EP0317376B2 (fr) *	1987-10-23	1996-04-03	Centre Regional De Transfusion Sanguine De Lille	Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
EP0442843B1 (fr) *	1990-02-14	1998-09-09	Pentapharm A.G.	Inhibiteur pour le prétraitement anticoagulant des échantillons sanguins
JP2758703B2 (ja) *	1990-07-31	1998-05-28	日本電気株式会社	音声合成器
EP0602173B1 (fr)	1991-09-05	1999-05-26	Baxter International Inc.	Composition a base de fibrinogene pour application topique
US5278289A (en)	1991-11-12	1994-01-11	Johnson Alan J	Antihemophilic factor stabilization
US5645540A (en) *	1994-10-11	1997-07-08	Stryker Corporation	Blood conservation system
US5736364A (en) *	1995-12-04	1998-04-07	Genentech, Inc.	Factor viia inhibitors
US5804400A (en) *	1996-02-05	1998-09-08	Igen International, Inc.	Electrochemiluminescent assay
JPH09286797A (ja)	1996-04-18	1997-11-04	Green Cross Corp:The	ヘパリンコファクターｉｉ及びその精製方法
AT403989B (de) *	1996-09-16	1998-07-27	Immuno Ag	Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
DE10012732A1 (de) *	2000-03-18	2001-09-20	Aventis Behring Gmbh	Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
IL136552A (en) *	2000-06-05	2005-05-17	Omrix Biopharmaceuticals Ltd	Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
DE10211632A1 (de) *	2002-03-15	2003-10-09	Aventis Behring Gmbh	Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
AT501088A2 (de) *	2002-12-18	2006-06-15	Bio Prod & Bio Eng Ag	Stabile therapeutische proteine

2002
- 2002-12-18 AT AT0189002A patent/AT501088A2/de not_active Application Discontinuation
2003
- 2003-12-18 WO PCT/AT2003/000374 patent/WO2004054607A2/fr not_active Ceased
- 2003-12-18 AU AU2003289742A patent/AU2003289742A1/en not_active Abandoned
- 2003-12-18 EP EP03781990.1A patent/EP1572229B1/fr not_active Revoked
- 2003-12-18 ES ES03781990.1T patent/ES2476815T3/es not_active Expired - Lifetime
- 2003-12-18 EP EP10014814A patent/EP2292255A3/fr not_active Withdrawn
- 2003-12-18 DK DK03781990.1T patent/DK1572229T3/da active
2005
- 2005-06-17 US US11/155,416 patent/US7795399B2/en not_active Expired - Fee Related
2010
- 2010-09-10 US US12/879,821 patent/US20110009324A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1572229A2 (fr)	2005-09-14
US7795399B2 (en)	2010-09-14
EP2292255A3 (fr)	2011-06-22
US20110009324A1 (en)	2011-01-13
ES2476815T3 (es)	2014-07-15
AU2003289742A1 (en)	2004-07-09
DK1572229T3 (da)	2014-06-23
WO2004054607A3 (fr)	2004-10-07
US20060009376A1 (en)	2006-01-12
EP1572229B1 (fr)	2014-04-30
EP2292255A2 (fr)	2011-03-09
WO2004054607A2 (fr)	2004-07-01

Legal Events

Date	Code	Title	Description
2024-06-15	REJ	Rejection	Effective date: 20240615

Publication	Publication Date	Title
AT501088A2 (de)	2006-06-15	Stabile therapeutische proteine
EP0253198B2 (fr)	1999-06-23	Colle pour tissu à un composant et son procédé de fabrication
EP0796623B1 (fr)	2005-05-25	Préparation pharmaceutique pour le traitement des maladies de la coagulation sanguine
EP0203509B1 (fr)	1991-04-03	Procédé pour la détermination quantitative de la protéine-C et une préparation activatrice pour sa réalisation
DE69805772T2 (de)	2003-01-30	Stabilisierte mischung auf fibrinogenbasis
DE2734821C3 (de)	1985-03-14	Blutgerinnungsfördernde Präparation und Verfahren zu ihrer Herstellung
DE19903693A1 (de)	1999-10-28	Protease zur Aktivierung des Gerinnungsfaktors VII
EP2293776B1 (fr)	2016-03-02	Fibrinogen étant fontionellement intact, stable au stockage et inactivé de virus
EP0018353B1 (fr)	1984-01-25	Procédé de préparation de fractions de plasma exemptes d'effets secondaires
DE3533516A1 (de)	1986-04-03	Blutgerinnungshemmende proteine, verfahren zur herstellung sowie deren verwendung
EP1275397B1 (fr)	2014-08-06	Médicament pour l'emploi local
AT405485B (de)	1999-08-25	Eine das vwf-propeptid enthaltende pharmazeutische präparation
DE69737500T2 (de)	2007-11-29	Gereinigte Multimerase
DE4430205A1 (de)	1996-02-29	Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
EP0833897A2 (fr)	1998-04-08	Derives de prothrombine
EP1528930B1 (fr)	2009-04-15	Preparations pharmaceutiques de substances actives a capacite de production de thrombine et contenant de la thrombine et medicaments
EP0626070B1 (fr)	1996-04-03	Procede de determination de l'hirudine et des inhibiteurs synthetiques de la thrombine
EP1405863A1 (fr)	2004-04-07	Concentré de facteur von-Willebrand comprenant de facteur VIII:C et son procédé de production
EP0972203B1 (fr)	2004-02-25	Reactif pour determiner le temps de cephaline active
EP1523327A1 (fr)	2005-04-20	Preparations de principes actifs pharmaceutiques et medicaments generant ou contenant de la thrombine
DE4418635C2 (de)	1997-07-24	Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
EP0570355B1 (fr)	1998-12-30	Utilisation des fragments prothrombines
WO2000049047A1 (fr)	2000-08-24	PROCEDE DE PRODUCTION D'UNE PREPARATION CONTENANT DU FACTEUR DE VON WILLEBRAND (vWF)
DE60006248T2 (de)	2004-07-29	Verwendung von fibrinogen-multimeren in fibrinklebern
CH525251A (de)	1972-07-15	Verfahren zur Herstellung einer therapeutisch aktiven Aspergillopeptidase zur Verhinderung der Bildung von Blutgerinnseln